Onyx Pharmaceuticals, Inc. has announced that the US FDA’s Oncologic Drug Advisory Committee (ODAC) has given a positive vote towards Kyprolis, which is being developed by Onyx Pharma for use in ...
Combined with Revlimid and dexamethasone, Kyprolis extended progression-free survival (PFS) by 8.7 months (from 17.6 months to 26.3 months), compared to Revlimid and dexamethasone alone.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback